Navigation Links
Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares
Date:10/20/2011


Adjusted net income for the third quarter of 2011, excluding these net charges, was $223 million, or $0.15 per share.

On a GAAP basis, net income for the third quarter of 2010 was $190 million, or $0.12 per share.  Reported results included intangible asset impairment charges, restructuring-related charges, discrete tax items, and amortization expense (after-tax) totaling $106 million, or $0.07 per share.  Adjusted net income for the third quarter of 2010, excluding these net charges, was $296 million, or $0.19 per share.

Guidance for Fourth Quarter and Full Year 2011The Company estimates sales for the fourth quarter of 2011 in a range of $1.850 to $1.950 billion.  Compared to sales for the fourth quarter of 2010, this range assumes a $64 million negative impact from the divestiture of the Neurovascular business.  Recent acquisitions are not expected to contribute significantly to fourth quarter sales.  The Company estimates earnings on a GAAP basis in a range of $0.05 to $0.11 per share.  Adjusted earnings, excluding restructuring-related net charges and amortization expense, are estimated in a range of $0.13 to $0.16 per share.  Recent acquisitions are expected to dilute fourth quarter 2011 adjusted earnings by approximately $0.01 per share as compared to the prior year, and the divestiture of the Neurovascular business is expected to dilute fourth quarter 2011 adjusted earnings by $0.01 per share.

The Company now estimates sales for the full year 2011 in a range of $7.624 to $7.724 billion.  Compared to full year 2010 sales, this range now assumes a $204 million negative impact from the divestiture of the Neurovascular business.  Recent acquisitions are not expected to contribute significantly to 2011 sales.  The Company now estimates earnings on a GAAP basis in a range of $0.27 to $0.33 per share.  Adjusted earnings, excluding goodwill and other intangible asset impair
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Boston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent
2. Boston Scientific Launches Promus Element™ Stent System In China
3. Boston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate
4. Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results
5. COPAN WASP® Lands at Prestigious Boston Medical Center
6. Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial
7. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent
8. Bluestar Silicones to Present Antimicrobial Silicones at Medical Silicones Conference in Boston
9. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
10. Boston Scientific Launches Coyote™ Balloon Catheter
11. Boston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... 21, 2013  Healthcare organizations expanding into emerging markets ... , India and ... no shortcuts.  This is proving particularly challenging, considering the ... must change the dialogue around BRIC, as it is ... and building regional partnerships to build a sustainable business. ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4
... NEW YORK, Sept. 28 Delcath Systems, Inc. (Nasdaq: ... the William Blair Emerging Growth Stock Conference on Tuesday, October ... Mr. David McDonald, Chief Financial Officer, will provide an overview ... Attendance at this conference is by invitation only. Delcath ...
... BOTHELL, Wash., Sept. 27 SCOLR Pharma, Inc. (NYSE ... Johnson has been appointed as the Chairman of its ... remain a member of the Board.   ... of Matrixx Initiatives, Inc. Under Johnson,s leadership, Matrixx successfully ...
Cached Medicine Technology:Delcath to Present at the William Blair Emerging Growth Stock Conference 2SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 2SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 3
(Date:5/21/2013)... Mecklenburg EMS Agency (Medic) and the ... Wellness Fair to educate the public on health initiatives and ... Wednesday, May 22, 2013 from 4:00 pm until 7:00 pm ... Creek Road, Charlotte, NC 29262). , Medic, the ... Mecklenburg County Department of Social Services are working toward ...
(Date:5/21/2013)... 2013 Arizona State University is ... to develop their ideas into solutions, products and ... The university is recruiting participants for AREA48 (Applied ... that provides early-stage entrepreneurs with opportunities to access ... to anyone, ASU is particularly seeking participation from ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to ... in the Creative Corridor region, is releasing results for ... conference on Thursday, May 23rd at 10:30 a.m. ... , The survey is a critical component ... that attract, nurture and retain people of diverse backgrounds, ...
(Date:5/21/2013)... the roles two proteins, thrombospondin-1 and prosaposin, play ... has identified a five-amino acid fragment of prosaposin ... of prostate, breast and lung cancer. The findings ... metastasis in a variety of cancers. , ... at Boston Children,s Hospital, Vivek Mittal, PhD, at ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Vinci surgery robot lawsuit is nearing its conclusion ... According to Bloomberg.com, during closing statements yesterday, an attorney ... dealership, alleging the company wanted to tie sales and ... do all the training to keep control of surgeons, ...
Breaking Medicine News(10 mins):Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 2Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 3Health News:Da Vinci Surgery Robot Lawsuit News: Bernstein Liebhard LLP Comments on Closing Arguments in Nation’s First Da Vinci Lawsuit Trial 4
... By Alan Mozes HealthDay Reporter , WEDNESDAY, ... suicide risk appears to be significantly higher among people ... The latest observation seems to confirm the findings of ... fully explained relationship between higher than average suicide rates ...
... hemorrhagic fever in humans, has no known cure or vaccine. ... scientists has uncovered a family of small molecules which appear ... inhibit its entry into human cells. The results are ... and are now online. Previous studies have shown ...
... Inserm research team in Toulouse, led by Dr Stein ... working with the "Modelling tissue and nociceptive stress" Host ... illusions described by many patients under regional anaesthetic. In ... Anesthesiology , the researchers demonstrated that anaesthetising an arm ...
... News) -- Many U.S. transplant surgeons unnecessarily shun organs ... safeguards that would protect and inform transplant recipients, a ... in the nation "overreacted" to a 2007 case in ... organs from a single donor unknowingly infected with HIV, ...
... January 20, 2011) Cancer scientists led by ... and collaborators at St Jude Children,s Research Hospital (Memphis) ... cells that carry them are organized in a more ... published today in Nature (DOI:10.1038/nature09733), challenge the ...
... By Charnicia Huggins HealthDay Reporter , ... tongue piercing as a form of self-expression, know that ... metal or plastic makes a difference when it comes ... collect more bacteria than plastic studs, potentially increasing the ...
Cached Medicine News:Health News:High Altitude Linked to Higher Suicide Risk -- Again 2Health News:High Altitude Linked to Higher Suicide Risk -- Again 3Health News:High Altitude Linked to Higher Suicide Risk -- Again 4Health News:Small molecules may prevent ebola infection 2Health News:How does anesthesia disturb self-perception? 2Health News:Cancer scientists discover genetic diversity in leukemic propagating cells 2Health News:Cancer scientists discover genetic diversity in leukemic propagating cells 3Health News:Metal Tongue Piercings Linked to Raised Infection Risks 2Health News:Metal Tongue Piercings Linked to Raised Infection Risks 3
Custom Pediatric Nebulizer Assembly W/Tubing...
... Patients over the age of 3 can choose ... STAR®. The same design principle applies to both:, ... and minimize aerosol output when the patient exhales ... optimum size to leave the nebulizer. The result ...
... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...
... Portex® medication nebulizers offer a spill-proof design ... to a 45° angle. All medical nebulizers ... wide variety of configurations are available., ... , ,Portex® medication nebulizers feature consistently ...
Medicine Products: